DPDavid J. Pulford

David J. Pulford

*This is an algorithmically generated author record based on publicly available information.

David J. Pulford has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patient stratification by genetic risk in Alzheimer’s disease is only effective in the presence of phenotypic heterogeneity

    by Jack Euesden, Muhammad Ali, Chloe Robins, Praveen Surendran, Padhraig Gormley, For The Alzheimer’s Disease Neuroimaging Initiative (Adni), David Pulford, Carlos Cruchaga

    Case-only designs in longitudinal cohorts are a valuable resource for identifying disease-relevant genes, pathways, and novel targets influencing disease progression. This is particularly relevant in Alzheimer’s disease (AD), where longitudinal cohorts measure disease “progression,” defined by rate of cognitive decline. Few of the identified drug targets for AD have been clinically tractable, and phenotypic heterogeneity is an obstacle to both clinical research and basic science. In four cohorts (n = 7241), we performed genome-wide association studies (GWAS) and Mendelian randomization (MR) to discover novel targets associated with progression and assess causal relationships. We tested opportunities for patient stratification by deriving polygenic risk scores (PRS) for AD risk and severity and tested the value of these scores in predicting progression. Genome-wide association studies identified no loci associated with progression at genome-wide significance (α = 5×10−8); MR analyses provided no significant evidence of an association between cognitive decline in AD patients and protein levels in brain, cerebrospinal fluid (CSF), and plasma. Polygenic risk scores for AD risk did not reliably stratify fast from slow progressors; however, a deeper investigation found that APOE ε4 status predicts amyloid-β and tau positive versus negative patients (odds ratio for an additional APOE ε4 allele = 5.78 [95% confidence interval: 3.76–8.89], P<0.001) when restricting to a subset of patients with available CSF biomarker data. These results provided no evidence for large-effect, common-variant loci involved in the rate of memory decline, suggesting that patient stratification based on common genetic risk factors for progression may have limited utility. Where clinically relevant biomarkers suggest diagnostic heterogeneity, there is evidence that a priori identified genetic risk factors may have value in patient stratification. Mendelian randomization was less tractable due to the lack of large-effect loci, and future analyses with increased samples sizes are needed to replicate and validate our results.


  • Top Cited Papers

    Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease

    by Daniel Western, Jigyasha Timsina, Lihua Wang, Ciyang Wang, Chengran Yang, Bridget Phillips, Yueyao Wang, Menghan Liu, Muhammad Ali, Aleksandra Beric, et al.

    The integration of quantitative trait loci (QTLs) with disease genome-wide association studies (GWASs) has proven successful in prioritizing candidate genes at disease-associated loci. QTL mapping has been focused on multi-tissue expression QTLs or plasma protein QTLs (pQTLs). We generated a cerebrospinal fluid (CSF) pQTL atlas by measuring 6,361 proteins in 3,506 samples. We identified 3,885 associations for 1,883 proteins, including 2,885 new pQTLs, demonstrating unique genetic regulation in CSF. We identified CSF-enriched pleiotropic regions on chromosome (chr)3q28 near OSTN and chr19q13.32 near APOE that were enriched for neuron specificity and neurological development. We integrated our associations with Alzheimer’s disease (AD) through proteome-wide association study (PWAS), colocalization and Mendelian randomization and identified 38 putative causal proteins, 15 of which have drugs available. Finally, we developed a proteomics-based AD prediction model that outperforms genetics-based models. These findings will be instrumental to further understand the biology and identify causal and druggable proteins for brain and neurological traits.


  • Open Access

    Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures for asymptomatic and symptomatic Alzheimer’s disease.

    by Carlos Cruchaga, Muhammad Ali, Yuanyuan Shen, Anh Do, Lihua Wang, Daniel Western, Menghan Liu, Aleksandra Beric, John Budde, Jen Gentsch, et al.

    Changes in Amyloid-β (A), hyperphosphorylated Tau (T) in brain and cerebrospinal fluid (CSF) precedes AD symptoms, making CSF proteome a potential avenue to understand the pathophysiology and facilitate reliable diagnostics and therapies. Using the AT framework and a three-stage study design (discovery, replication, and meta-analysis), we identified 2,173 proteins dysregulated in AD, that were further validated in a third totally independent cohort. Machine learning was implemented to create and validate highly accurate and replicable (AUC>0.90) models that predict AD biomarker positivity and clinical status. These models can also identify people that will convert to AD and those AD cases with faster progression. The associated proteins cluster in four different protein pseudo-trajectories groups spanning the AD continuum and were enrichment in specific pathways including neuronal death, apoptosis and tau phosphorylation (early stages), microglia dysregulation and endolysosomal dysfuncton(mid-stages), brain plasticity and longevity (mid-stages) and late microglia-neuron crosstalk (late stages).


  • Open Access

    Identification of novel genetic variants and biomarkers for cognitive decline in Alzheimer’s disease

    by Muhammad Ali, Fengxian Wang, Samira Mafimoghaddam, Jack Euesden, Chloe Robins, David J. Pulford, Carlos Cruchaga

    Background: Alzheimer’s disease (AD) is a complex, multifactorial disease that is incurable in the aging population. The success of genome‐wide association studies (GWAS), as a cross sectional design, to identify novel genetic risk factors for AD in recent years is well known; however, case‐control studies are less likely to uncover genetic factors that influence other aspects of the disease, such as progression and onset.Method: In order to identify common and rare genetic variants associated with rates of cognitive decline in AD, we aim at systematically analyzing the largest collection of longitudinal and GWAS data (N = 7,241), across non‐Hispanic white individuals from multicenter cohorts (Knight‐ADRC, ADNI, NACC, and GSK) with at least 1.5 years of follow up after being diagnosed with AD. We also aim at exploring if genetic risk factors, alone or interacting with other genetic factors, are associated rate of cognitive decline in patients with AD when aggregated together into a single Polygenic Risk Score (PRS). Furthermore, external proteomics data will be combined with the genetics data for Mendelian Randomization (MR) analyses in order to discover causal biomarkers for cognitive decline and AD risk.Result: Preliminary results found a suggestive signal in chr21 (min P = 8.7e‐8) approaching close to the genome‐wide significance threshold. Moreover, some other suggestive signals were detected in chr2 (min P = 3.8e‐06) and chr1 (min P = 3.7e‐06) that warrant further investigation. Further results and key findings of the post‐GWAS analyses will be presented during the AAIC meeting.Conclusion: We have leveraged these datasets to generate prediction models for rate of cognitive decline in AD. The identification of AD‐specific genetic variants and biomarkers will enable the characterization of appropriate therapeutic targets for slowing or halting the AD progression.